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ABSTRACT 23 
 24 
The murine model of cyclosporine A (CsA)-induced syngeneic graft-versus-host 25 
disease (SGVHD) is a bone marrow transplantation (BMT) model that develops chronic 26 
colon inflammation identical to other murine models of CD4+ T cell-mediated colitis.  27 
Interestingly, SGVHD animals develop chronic liver lesions that are similar to the early 28 
peribiliary inflammatory stages of clinical chronic liver disease which is frequently 29 
associated with inflammatory bowel disease (IBD). Therefore, studies were initiated to 30 
investigate the chronic liver inflammation that develops in the SGVHD model.  To 31 
induce SGVHD, mice were lethally irradiated, reconstituted with syngeneic BM and 32 
treated with CsA.  All of the SGVHD animals that developed colitis also develop chronic 33 
liver inflammation.  Liver samples from control and SGVHD animals were monitored for 34 
tissue pathology, RNA for inflammatory mediators and phenotypic analysis and in vitro 35 
reactivity of the inflammatory infiltrate.  Diseased animals developed lesions of intra- 36 
and extrahepatic bile ducts.  Elevated levels of mRNA for molecules associated with 37 
chronic liver inflammation including mucosal cellular adhesion molecule -1, the 38 
chemokines CCL25, CCL28, CCR9 and TH1 and TH17 associated cytokines were 39 
observed in livers of SGVHD mice.  CD4+ T cells were localized to the peribiliary region 40 
of the livers of diseased animals and an enhanced proliferative response of liver 41 
associated mononuclear cells against colonic bacterial antigens was observed.  The 42 
murine model of SGVHD colitis may be a valuable tool to study the entero-hepatic 43 
linkage between chronic colon inflammation and inflammatory liver disease. 44 
 45 
 46 
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INTRODUCTION 51 
 52 
Clinically a high percentage of IBD patients also present with some form of 53 
portal/periportal liver inflammation including autoimmune hepatitis (AIH), primary 54 
sclerosing cholangitis (PSC) and occasionally primary biliary cirrhosis (PBC) (30).  In a 55 
recent study, elevation of serum aminotransferase was found in one third of 500 IBD 56 
patients (39).  Primary sclerosing cholangitis and AIH are common extraintestinal 57 
manifestations of IBD, with the majority of PSC patients having IBD (>75%); ulcerative 58 
colitis is present in most (~90%), with Crohn’s Disease being present in the rest (5, 17).  59 
While PSC is typically diagnosed after the diagnosis of IBD, the diagnosis of PSC can 60 
precede IBD by several years (30).  Autoimmune hepatitis is a more classic 61 
autoimmune disease but some patients can be diagnosed with features of both PSC 62 
and AIH as an overlap disorder. These forms of chronic liver disease are characterized 63 
by portal/periportal inflammation that can lead to fibrosis.   64 
 65 
IBD-associated chronic liver inflammation such as PSC appears to be mediated 66 
by IFN-γ-producing, microbial-antigen-specific CD4+ T cells activated in the gut and 67 
recruited to the liver by aberrant expression of mucosal addressin cellular adhesion 68 
molecule 1 (MAdCAM-1) and chemokines (CCL25) that are typically expressed in the 69 
gut (reviewed (1)).  Upregulation of these molecules on the portal endothelium of the 70 
liver enables the recruitment of α4β7+, CCR9+, CD4+ memory T cells to the liver from 71 
the gut (1).  α4β7 and CCR9 are the ligands for MAdCAM and CCL25, respectively.  It 72 
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has been postulated that Toll-like receptors (TLR) on immune (macrophages, Kuppfer 73 
cells, dendritic cells (DC)) and non-immune cells (cholangiocytes) in the liver are 74 
exposed to bacteria/bacterial products via entero-hepatic circulation and bind pathogen-75 
associated molecular patterns (PAMPs), become activated and secrete proinflammatory 76 
cytokines and chemokines (TNF-α, IL-1β, IL-6; CCL25) (42) that can participate in the 77 
recruitment of adaptive immune cells to the liver (28).      78 
 79 
Animal models have been developed to understand the pathophysiology 80 
associated with chronic liver inflammation.  One class utilizes bacterial wall components 81 
and develop biliary sclerosis after bacterial overgrowth of the small bowel (35) or 82 
following injection of bacterial products and induction of experimental colitis in rats and 83 
rabbits (36).  Non-suppurative destructive cholangitis is the main lesion during murine 84 
allogeneic GVHD (58).  The injection of 2,4,6-trinitrobenzene sulphonic acid (TNBS) into 85 
the extra-hepatic bile duct induces an antigen-specific immune response that is similar 86 
to PSC clinically, including a CD4+ TH1 immune response with stricturing of hepatic bile 87 
ducts and induction of portal fibrosis (43).  In addition to models of PSC, other murine 88 
models have been developed to simulate AIH.  The intravenous injection of conconavilin 89 
A (32) or the injection of antigen-specific T cells into transgenic mice that express novel 90 
antigen on the surface of hepatocytes results in the development of T cell mediated AIH 91 
(11).  More recently PBC was shown to develop in IL-2Rα-/- animals. In this model the 92 
CD8+ effector cells differentiated in the liver and appeared not to be recruited from other 93 
sites (59).   94 
 95 
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Inflammatory bowel disease represents a chronic inflammation of the intestinal 96 
tract of unknown origin.  It has been recognized that IBD results from a dysregulated 97 
immunological response to commensal bacteria in genetically susceptible individuals 98 
(48).  Experimentally, colitis develops in chemically treated and gene knockout animals, 99 
and following adoptive transfer of naïve CD4+ T cells into immune deficient recipients 100 
(reviewed (49)).  The majority of these models have been thought to develop as a result 101 
of a TH1 cytokine-based immune response that is characterized by excessive 102 
production of IL-12/IFN-γ/TNF-α.  Recently, however, it has been shown that in addition 103 
to TH1 cells, a distinct population of IL-17-producing CD4+ T cells (TH17 cells) can drive 104 
intestinal inflammation (reviewed (23)).   105 
 106 
In murine SGVHD a colitis-like disease developed following lethal irradiation, 107 
syngeneic BMT and a short course of CsA therapy (7, 18, 19).  Clinical symptoms 108 
(weight loss, diarrhea) typically occurred in 80-100% of the CsA-treated animals, with 109 
lymphocytic infiltration of the colon and liver being observed. In vivo depletion and 110 
adoptive transfer studies demonstrated that CD4+, but not CD8+ T cells played a 111 
prominent role in the development of murine SGVHD-associated colitis (6, 10).  Similar 112 
to murine colitis models, recent studies have demonstrated enhanced responsiveness 113 
of SGVHD CD4+ T cells against antigens isolated from cecal bacterial preparations (6), 114 
leading to the speculation that CD4+ T cells reactive against bacterial antigens mediate 115 
the chronic intestinal and liver inflammation observed during murine SGVHD.    116 
 117 
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There currently are no established animal models of IBD-associated chronic liver 118 
inflammation.  In this manuscript, data is presented that demonstrates an absolute 119 
linkage between liver inflammation and colitis in the SGVHD model and test the 120 
hypothesis that microbial-specific T cells migrate from the colon to the liver to induce 121 
chronic liver inflammation.  Chronic liver inflammation of intrahepatic/extrahepatic bile 122 
ducts was associated with the aberrant expression of colon-associated 123 
CAM/chemokines and a TH1/TH17 inflammatory immune response. Given the complete 124 
entero-hepatic linkage, the role of CD4+ T cells in the SGVHD disease model and the 125 
similarity in inflammatory response/lesions with the early lesions associated with clinical 126 
PSC, murine SGVHD is a useful model in which to study the immune mechanisms that 127 
are essential for the initiation and maintenance of chronic liver inflammation during IBD. 128 
 129 
 130 
 131 
 132 
 133 
 134 
 135 
 136 
 137 
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MATERIALS and METHODS 138 
 139 
Animals. Female C3H/HeN mice were purchased from Harlan (Indianapolis, IN) 140 
at 19-21 days of age and were used within 1 week of arrival.  Animals were housed in 141 
sterile microisolator cages (Lab Products, Maywood, NJ) and were fed autoclaved food 142 
and acidified water ad libitum.  All animal protocols were approved by the University of 143 
Kentucky Institutional Animal Care and Use Committee. 144 
 145 
Induction of SGVHD.  Bone marrow (BM) was isolated from the femurs and tibias 146 
of syngeneic age matched mice.  Donor BM suspensions were prepared in RPMI 1640 147 
(Cellgro, Herndon, VA) containing 100 U/ml penicillin and 100 μg/ml streptomycin and 2 148 
mM glutamine (GIBCO, Grand Island, NY) and depleted of Thy-1+ BM cells as 149 
previously described (8).  To induce SGVHD, recipient mice were lethally irradiated (900 150 
cGy) in a Mark I 137Cs irradiator (J.L. Shepherd and Associates, Glendale, CA).  151 
Following irradiation, the animals were reconstituted i.v. with 5x106 syngeneic T cell 152 
depleted BM (ATBM) cells, 4-6 h after conditioning.  Beginning on the day of BMT, the 153 
mice were treated daily i.p. for 21 days with 15 mg/kg/day of CsA or the diluent olive oil 154 
(Sigma-Aldrich, St. Louis, MO).  Upon cessation of CsA therapy, the BMT control and 155 
CsA-treated animals were weighed 3 times per week and monitored for the 156 
development of clinical symptoms of SGVHD (weight loss, diarrhea).  Animals that 157 
developed clinical symptoms for three consecutive weighings were considered positive 158 
for the induction of SGVHD.   159 
 160 
 161 
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Histological Analysis of SGVHD Inflammation. Tissues were removed from 162 
euthanized animals at the indicated times after BMT and cessation of CsA therapy and 163 
placed into 10% buffered formalin.  The fixed tissues were embedded in paraffin, cut 164 
into 4-6 μm sections, mounted onto glass slides and stained with a standard H&E 165 
protocol.  All slides were analyzed blindly and were graded for inflammation according 166 
to a previously published grading scale (9). 167 
 168 
Immunohistochemical Staining. Liver samples were taken and immediately 169 
embedded in Tissue-Tek Optimal Cutting Temperature (O.C.T.) Compound (Sakura 170 
Finetek, Torrance CA) and frozen in liquid nitrogen. Samples were then cut into 10-µm 171 
tissue sections, mounted on glass slides and stored in -20⁰C freezer. Tissues were fixed 172 
with 3% paraformaldehyde for 15 minutes followed by 3 x 5 minute washes in PBS.  173 
Slides were blocked to prevent non-specific binding with 2 mg/ml normal donkey serum 174 
(Jackson ImmunoResearch, West Grove, PA), 0.3% Triton X-100 in PBS for 30 minutes 175 
4°C. Slides were then incubated with FITC-conjugated mAb against CD4 (GK1.5; BD 176 
PharMingen, San Diego, CA) (1:1000) in PBS supplemented with 2 mg/ml normal 177 
donkey serum and 0.3% Triton X-100 at 4⁰C overnight in a humidified chamber.  Control 178 
staining was performed by using FITC IgG Rat antibody (1:1000).  After 2 washes in 179 
PBS, the samples were visualized on a Carl Zeiss microscope 100x magnification and 180 
digitized with the camera AxioVision HR. Because the automatic exposure setting on 181 
the microscope camera overcompensated for tissues without T cell infiltration, post-182 
capture image processing was used to adjust tissue section images to the equivalent 183 
levels of background fluorescence. 184 
 185 
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Quantification of Serum Markers. Serum/plasma ALT concentrations were performed as 186 
per manufactures instructions. Briefly 100 μl of serum was mixed with 1ml of 37oC pre-187 
warmed ALT (SGPT) reagent (Pointe Scientific, Canton, MI, USA) and further incubated 188 
at 37oC for 1 minute before the absorbance at 340 nm was read.  An additional 2 189 
absorbance readings (340 nm) were taken 1 minute apart with the sample being 190 
incubated at 37oC between readings. The ALT concentration (IU/L) was calculated by 191 
multiplying the average absorbance difference per minute (Δabs/min.) by the factor 192 
1768.  193 
 194 
Levels of anti-ssDNA in the serum/plasma of SGVHD mice were determined by 195 
ELISA.  Briefly, wells of a 96-well plate were coated with 100 µl of ssDNA (heat 196 
denatured salmon sperm DNA at 10 µg/ml in citrate phosphate buffer, pH 5.0). The 197 
plates were incubated at 4°C overnight.  After washing the plates were washed 2X with 198 
tris-buffered saline containing 0.3% Tween-20 (TBS-T (pH 7.6)). Plates were blocked 199 
with 1.0% BSA in TBS for 1 hour at room temperature. Plates were washed with TBS-T 200 
and experimental samples were diluted 1/20 in TBS-T containing 0.25% BSA and 100 µl 201 
were added per well for 2 hours at room temperature. (The standard positive control 202 
was pooled serum from (3H9 × CD5-\- ) F1 mice at different dilutions (4)). Plates were 203 
washed with TBS-T and alkaline phosphatase-conjugated goat anti-mouse Ig (heavy 204 
and light chain), diluted 1/1000 in TBS-T with 0.25% BSA was added to each well for 2 205 
hours at room temperature. Plates were washed with TBS-T and 2X with TBS. p-206 
nitrophenyl phosphate (pNPP) was diluted to 1 mg/ml in substrate buffer (Phenylamine 207 
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buffer, pH 9.8) and added to each well for 30 minutes at room temperature and the 208 
absorbance was read at 405 nm.  209 
 210 
Detection of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) was 211 
performed on ethanol fixed human neutrophil substrate slides (INOVA Diagnostics, San 212 
Diego, CA). Substrate slides were placed in a humidified chamber and 20 ul of either 213 
sample serum/plasma, positive or negative controls (INOVA Diagnostics) was added to 214 
the corresponding wells and incubated for 30 minutes at room temperature. Slides were 215 
then washed twice in PBS. Mouse IgG anti-bodies were detected by FITC-conjugated 216 
goat anti-mouse IgG antibodies (Sigma, St. Louis, MO) or goat anti-human IgG 217 
antibodies for positive controls (Sigma). After 30 minute incubation the slides were 218 
washed twice in PBS and analyzed using a Carl Zeiss microscope at 200x magnification 219 
and digitized with the camera AxioVision HR. The grading of the p-ANCA results was 220 
determined by the level of fluorescence as described by the manufacturer.    Depending 221 
on the intensity of the staining the sample was given a fluorescent grade. Intensity 222 
grading criteria for fluorescence is as follows; brilliant fluorescent staining of nucleus 223 
(grade 4), bright fluorescent staining of nucleus (grade 3), nuclear staining clearly 224 
distinguishable, but not bright green (grade 2), lowest specific fluorescence that allows 225 
the differentiation of the nucleus from the background staining (grade 1), no distinction 226 
between the nucleus and background staining (grade 0). For this study a sample that 227 
had been graded 2 to 4 was considered positive and those samples graded either 0 or 1 228 
were considered negative for p-ANCA.   229 
 230 
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 Analysis of Cytokine Gene Expression by Real-time PCR. Total mRNA was 231 
isolated from the livers using Trizol reagent (Invitrogen, Grand Island, NY).  mRNA (1 232 
μg) from each group was reverse-transcribed into cDNA using the Promega (Madison, 233 
WI) reverse transcription system.  cDNA was suspended in 1x master mix (0.5U 234 
Platinum Taq (Invitrogen), 0.2 nM of each dNTP, 0.2 mM PCR buffer (Idaho 235 
Technology, Inc., Salt Lake City, UT), 1x SYBR green (Molecular Probes, Eugene, OR).  236 
The reaction volume was made to 10 μl with ddH20.  Primers for IL-12, IFN-γ, TNF-α 237 
(21), IL-17, IL-23p19, CCR9, CCL25, CCL28, MAdCAM-1 and GADPH (44) were 238 
purchased from Integrated DNA Technologies (Coralville, IA) and were used at 1 μM 239 
concentration.  Real-time PCR was performed on a Roche Lightcycler (Roche 240 
Diagnostics, Indianapolis, IN).  Reaction conditions were as follows: 1 min at 950C 241 
followed by 50 cycles of 6s at 950C, 10s at 600C and15s at 720C.  All the primers listed 242 
were normalized to GADPH and their expression calculated by the comparative CT 243 
method. 244 
 245 
Isolation of Liver-Associated Mononuclear (LAM) Cells. Livers were isolated from 246 
control BMT or SGVHD mice at 2-4 weeks after cessation of CsA therapy and perfused 247 
with 5 ml digestion buffer (RPMI 1640, 5% FCS, 0.05% collagenase IV (Sigma), 0.002% 248 
DNAse I (Sigma-Aldrich) then single cell suspensions were prepared in digestion buffer.  249 
The liver homogenate was placed into 50 ml centrifuge tubes and placed in a 370C 250 
water bath for 40 min with intermittent shaking.  The cells were washed twice and the 251 
pellet was resuspended in 32% Percoll and centrifuged for 20 min at 2000 rpm at room 252 
temperature.  The pellet was treated with 0.83% Tris-buffered NH4Cl to remove RBC.  253 
After washing the cells were placed into 10% complete RPMI (10% FCS, 100 U/ml 254 
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penicillin and 100 μg/ml streptomycin and 2 mM glutamine, 5x10-5 M of 2-ME) for use in 255 
in vitro proliferation assay and flow cytometric analysis. 256 
 257 
Proliferation Assay.  A cecal bacterial antigen (CeAg) preparation was prepared 258 
according the procedure described by Cong et al (13).  Bone marrow-derived dendritic 259 
cells (DC) were generated by culturing C3H/HeN BM cells in RPMI 1640 containing 5% 260 
FCS, penicillin/streptomycin/glutamine, and 5 mM 2-ME containing 20 ng/ml of 261 
recombinant murine GM-CSF.   The non-adherent cells were removed on days 3 and 5 262 
and GM-CSF containing media was added.  At 8-10 days after initiation of culture, cecal 263 
antigen-pulsed DC were prepared by incubation of DC over night with 200 mg/ml of 264 
CeAg (6).  This dose of CeAg was the minimal dose required to induce maximal 265 
proliferative response of CD4+ T cells from SGVHD animals.  Furthermore, incubation of 266 
the DC with CeAg resulted in the maturation of DC resulting in increased expression of 267 
MHC class II and B7 costimulatory molecules (J.S. Bryson, unpublished observation).   268 
To determine the proliferative capacity of LAM against bacterial antigens, 2 x 105 LAM 269 
from control or SGVHD mice were cultured with 1 x 104 irradiated (2000 cGy) DC or 270 
CeAg –pulsed DC in a 96 well flat bottomed plate. Proliferation was measured by the 271 
addition of [3H]-thymidine during the last 18 h of a 96 h culture. 272 
 273 
Flow Cytometry. LAM cells were harvested and placed into staining buffer (PBS 274 
containing 1% FBS, 0.1% NaN3).  To minimize non-specific staining, cells were 275 
incubated with Ab against CD16/CD32 (2.4G2, Fc Block®, BD PharMingen).  The cells 276 
were stained with antibodies against CD4 (RM-4-5) (Caltag, Burlingame, CA), CD8 (CT-277 
CD8, Caltag), CD11b (M1/70), CD11c (BD PharMingen), TLR2 (eBioscience, San 278 
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Diego, CA) or TLR5 (Imgenex, San Diego, CA) then analyzed by flow cytometry. To 279 
detect invariant natural killer T cells (iNKT), LAM were stained with αβTCR (H57-597 280 
(BD PharMingen)) and α-GalCer loaded CD1 tetramers or unloaded CD1 tetramers 281 
(kindly provided by Dr Mitch Kronenberg, La Jolla Institute for Allergy and Immunology, 282 
San Diego, CA)(38).  To determine intracellular cytokine production isolated LAM were 283 
placed in complete RPMI growth media and stimulated with anti-mouse CD3 ascites for 284 
8 hours at 37oC.  2 μM monensin (eBioscience) was added during the last 4 hours of 285 
culture and  the cells were harvested, counted and placed in staining buffer (PBS 286 
containing 1% FCS, 0.1% NaN3).  To reduce nonspecific staining, cells were incubated 287 
with Ab against CD16/CD32 (Fc Block).  1 x 106 cells were then stained with 288 
fluorochrome-conjugated mAb against CD4 (Caltag Burlingame CA).  Intracellular 289 
staining for IL-17, IFN-γ and TNF-α was performed using an Intracellular Cytokine 290 
Staining Kit (eBioscience, San Diego, CA) according to manufacturer’s directions.  291 
Stained cells were analyzed using a BD Biosciences FACSCalibur flow cytometer (San 292 
Jose, CA).  293 
 294 
Statistical Analysis. Statistical differences between groups were determined 295 
using Student’s t test.  Differences ≤ 0.05 were considered statistically different. 296 
297 
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RESULTS 298 
   299 
Chronic Liver Pathology Associated with SGVHD. In addition to CD4+ T cell-300 
mediated inflammation in the epithelium and lamina propria of the colon (Fig. 1B vs 301 
1A)(8, 10) with similarity to that observed in other models of murine colitis, significant 302 
and reproducible chronic inflammatory lesions are observed in the livers of SGVHD 303 
mice.  As opposed to other murine models of colitis where chronic liver inflammation 304 
was observed in ~30% of the animals (40), histological analysis of both the colons and 305 
livers of SGVHD mice showed an absolute correlation between colitis and liver 306 
inflammation (9/9 in the current study).  As shown in Figure 1, the inflammation 307 
described for samples taken in the first 2-4 weeks (Fig. 1D) after induction of SGVHD 308 
resembles the initial portal stage of clinical PSC, with inflammation limited to the portal 309 
area with no fibrosis being present (50).  The lesions demonstrated significant portal 310 
lymphoid infiltrates in and around the intra-hepatic bile ducts with cholangiocyte 311 
necrosis (Fig. 1D).   Liver samples taken at 8 weeks after cessation of CsA therapy (Fig. 312 
1E (H&E) and 1F (Trichrome)) show extension beyond the limiting plate, resembling the 313 
periportal stage (II) of PSC (50). In contrast, an occasional lymphocyte can be observed 314 
outside the bile ducts of transplant control animals (Fig.1C) with no significant 315 
inflammatory response being observed.  Examination of the extrahepatic bile ducts 316 
taken from the SGVHD animals showed apoptotic changes along with the bile duct 317 
invasion by inflammatory cells (Fig 1H). Inflammatory debris was also present in the 318 
lumen as well as inflammatory cells being located in the surrounding adventitia.  319 
Minimal inflammation was detected in the extrahepatic bile ducts isolated from the 320 
control BMT animals (Fig 1G).  As shown previously (9), a significantly higher pathology 321 
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grade was observed in the colon and livers obtained from the SGVHD vs BMT control 322 
animals (Fig. 2). Although slightly reduced in severity, similar changes and pathology 323 
grades were observed 1 week after cessation of CsA therapy, prior to clinical symptoms 324 
of SGVHD (J.S. Bryson, unpublished observations). 325 
 326 
Similar to what is observed clinically in patients with chronic liver inflammation, 327 
elevated levels of ALT were observed in the serum/plasma from SGVHD versus control 328 
BMT animals (Fig. 3A left panel).  These increases were associated with the liver 329 
pathology observed in these animals (Fig. 1, 2) and were significantly elevated in 330 
SGVHD mice.  Similar to the increased presence of liver enzymes, significantly 331 
increased levels of the autoantibody, anti-ssDNA (Fig 3B left panel), and importantly, 332 
perinuclear ANCA (p-ANCA), was observed during active disease as well (92% vs 333 
10%)(Fig. 3C left panel).  No differences in the levels of ALT, anti-ssDNA or p-ANCA 334 
autoantibodies were observed between control and CsA-treated animals one week after 335 
cessation of CsA therapy.  However, the levels of these mediators increased with time 336 
after cessation until they were significantly increased by 5-6 weeks after induction 337 
therapy (Fig. 3 A-C right panels).  Changes in ALT and p-ANCA have been associated 338 
with the development of chronic liver and colon inflammation including AIH and PSC 339 
(52, 54, 61).   340 
  341 
Phenotypic Analysis of LAM Isolated from SGVHD Animals. In addition to studies 342 
monitoring pathology and liver-associated inflammatory markers, preliminary studies 343 
were initiated to monitor phenotypic changes that occur in the cellular immune response 344 
in the SGVHD liver.  Liver associated mononuclear cells were isolated from transplant 345 
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control and SGVHD mice and monitored for the presence of CD4+, CD8+, NKT cells, 346 
macrophages and neutrophils.  No significant change was observed in CD4+, CD8+ (Fig 347 
4A) and neutrophils (J. Bryson, unpublished observations) between BMT controls and 348 
SGVHD animals.  However, while the number of CD4+ T cells did not change, 349 
immunohistochemistry analysis showed that CD4+ T cells were primarily localized 350 
around the hepatic bile duct in the SGVHD liver (Fig 4D; arrows) compared to being 351 
more diffusely dispersed thought the BMT control liver (Fig 4C).  In addition, while no 352 
apparent changes in T cell numbers were observed in the SGVHD liver, a significantly 353 
decreased proportion of iNKT cells staining with α-GalCer-CD1d tetramers, in LAM from 354 
BMT control vs SGVHD mice (Fig 4E).  These cells have been shown to be involved in 355 
development of oral tolerance (29, 57) and increase in SGVHD mice that recover from 356 
colitis (~30% of diseased animals) (J. Bryson, unpublished observations).  Finally, 357 
significantly increased percentages of CD11b+ (Fig. 4F) or CD11b+GR-1- 358 
myeloid/macrophage cells were observed in LAM from SGVHD vs control animals.  As 359 
activation of innate effector cells via signaling through Toll-Like Receptors (TLR) may 360 
play a significant role in the generation of adaptive immunity and more pointedly in the 361 
initial stages of PCS pathology (53), increases in macrophages may be significant in the 362 
development in SGVHD-associated liver inflammation.   363 
 364 
TLR Expression in SGVHD. Gram positive and Gram negative bacteria were 365 
found in a significantly higher percentage of the livers from CsA-treated versus control 366 
animals  (18).  As bacteria are a significant source of TLR ligands (Pathogen-associated 367 
molecular patterns (PAMPs)) it is likely that liver macrophages (Kupffer cells) and other 368 
tissue cells come into contact with PAMPs resulting in activation and secretion of 369 
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inflammatory mediators.  Real time PCR studies demonstrated that mRNA for all TLRs 370 
(1-9) was increased in the liver and colon of SGVHD mice. Importantly, mRNA for four 371 
of the five TLR’s that are associated with binding bacterial PAMPs, TLR-1 (J. Bryson, 372 
unpublished observations), 2, 5 and 9, were significantly increased (Supplementary 373 
Data, Fig. 1). Finally, while antibodies are not available for all TLR, flow cytometry 374 
studies were performed using antibodies against TLR-2 and TLR5 to determine the 375 
nature of the LAM cells expressing these TLR. A significant increase in TLR2 and 5 376 
staining was found in CD11b+ cells isolated from the livers of SGVHD versus control 377 
BMT animals (Supplementary Data, Fig. 2).  378 
 379 
Increased Inflammatory Mediators in Livers of SGVHD Mice. It has been widely 380 
suggested that IBD-associated chronic liver inflammation is mediated by TH1 CD4+ T 381 
cells (42).  Initial studies demonstrated that SGVHD-mediated colon inflammation could 382 
be mediated by TH17 or TH1 immune responses (Brandon et al. Development of a TH17 383 
immune response during the induction of murine syngeneic graft-versus-host disease, 384 
Submitted for publication).  To determine the nature of the T helper immune response in 385 
the SGVHD liver, LAM were isolated from control and diseased animals, stimulated and 386 
analyzed for the production of IL-17 (TH17) or IFN-γ (TH1) by intracellular cytokine 387 
staining techniques.  As shown in Figure 5A, significantly increased percentages of both 388 
IL-17- and IFN-γ-producing CD4+ T cells were observed in LAM isolated from SGVHD 389 
versus control animals.  To support and expand these findings, mRNA was isolated 390 
from control and SGVHD livers and analyzed by real time PCR for TH17 and TH1 391 
cytokines and inflammatory mediators that are associated with mucosal/liver 392 
inflammation.  In the SGVHD liver there was a significant increase in mRNA  for IFN-γ 393 
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(p=0.0009) as previously published in this model (19) and as demonstrated clinically 394 
(42).  Since TH17 cells have been shown to be elevated in IBD (20, 27) and in the 395 
SGVHD liver (Fig 5A), we sought to monitor the levels of TH17-associated cytokines.  396 
Real time PCR analysis of liver RNA demonstrated increased expression of mRNA for 397 
IL-17 (p=0.0075), IL-23p19 and TNF-α (Fig 5B).  In addition, increased mRNA for IL-398 
12p40 (Fig 5B), a subunit for both IL-23 and the TH1 cytokine IL-12 was found to be 399 
significantly increased in diseased livers as well.    Finally inflammatory chemokines and 400 
chemokine receptors involved in mucosal T cell homing (CCL25, CCL28 and CCR9) 401 
(Fig 6 A, B and D) were also increased in the livers of SGVHD mice compared to control 402 
animals.  The increase in the expression of mRNA for CCR9 was also associated with a 403 
significant increase in the expression of CD4+ LAM expression CCR9 (Fig. 4B) isolated 404 
from SGVHD animals.  In line with the increase in gut homing chemokines, mRNA for 405 
MAdCAM, a CAM that has been associated with aberrant homing of lymphocytes to the 406 
liver of PSC patients (1, 16) was also significantly elevated in the SGVHD liver (Fig 6B).  407 
A corresponding increase (p=0.0557) in the percentage of CD4+ expressing the ligand 408 
for MAdCAM, β7 integrin, was observed in the LAM from diseased versus control 409 
animals (Fig. 4B).  Thus, there was an increase in CD4+ T cells in the SGVHD liver that 410 
have a phenotype typical of effector cells that are derived in the intestinal tract. 411 
 412 
We have observed that at the end of the CsA therapy (d21 post-BMT), prior to 413 
the development of clinical symptoms, there are increases in the expression levels of 414 
mRNA for proinflammatory cytokines, chemokines and adhesion molecules in the 415 
colons of SGVHD animals (Perez et al. Accumulation of CD4+ T cells in the colon of 416 
CsA-treated mice following myeloablative conditioning and bone marrow 417 
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transplantation. Submitted for publication).  It is proposed that during PSC, CD4+ T cells 418 
migrate to the liver following activation in the colon via aberrant hepatic expression of 419 
MAdCAM and CCL25 (1)(Fig. 6).  To investigate when T cells migrate into the liver of 420 
CsA-treated animals, liver tissue isolated from CsA-treated/SGVHD and control animals 421 
at 14, 21 and 37 days after BMT was stained for CD4+ T cells.  CD4+ T cells were rarely 422 
observed in livers from control or CsA-treated animals at 14 and 21 days after BMT 423 
(Fig. 7A).  Conversely, CD4+ T cells were easily detected around the bile ducts (arrow) 424 
of diseased animals (37 days or 2-3 wks post-CsA) as was shown in Figure 7A.  425 
Furthermore, based on PCR analysis, MAdCAM mRNA was not elevated at day 14 426 
post-BMT (J. Bryson, unpublished observations) and both MAdCAM and CCL25 427 
trended towards increased levels in the liver of CsA-treated mice by day 21 post-BMT 428 
(Fig. 7B).  Together, these findings suggest that an ordered expression of chemokines 429 
and CAM results in the timed migration of CD4+ T cells into the liver.   430 
 431 
LAM from SGVHD Mice Display Increased Microbial Reactivity. Previous studies 432 
have demonstrated increased proliferation of peripheral SGVHD CD4+ T cells against 433 
bacterial antigens (6).  Since it is known that increased bacteria were present in the 434 
livers of CsA treated animals (18), studies were performed to analyze the anti-bacterial 435 
antigen-specific proliferation of LAM isolated from SGVHD mice.  LAM isolated from the 436 
livers of SGVHD mice demonstrated a significantly enhanced proliferative response 437 
against cecal bacterial antigens compared to control liver cells (p=0.0002) (Fig.8).   438 
 439 
 440 
  441 
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DISCUSSION 442 
 443 
Chronic inflammatory processes of the liver are frequently associated with IBD 444 
(30).  The current study describes the pathogenesis of chronic liver lesions that develop 445 
during the induction of murine SGVHD.  Murine SGVHD is a unique model of colon 446 
inflammation with 100% penetrance of chronic liver inflammation that involves intra- and 447 
extrahepatic bile ducts.  SGVHD-mediated liver disease was associated with increased 448 
ALT and p-ANCA levels similar to clinical markers of chronic liver inflammation.  Liver 449 
mRNA levels of molecules associated with chronic inflammation and lymphocyte 450 
migration were increased along with TH1 and TH17-associated immune responses. 451 
Finally, increased reactivity of hepatic LAM to colonic bacterial antigen- pulsed DC’s 452 
was observed suggesting that in SGVHD, microbial antigen-specific T cells may be 453 
responsible for the chronic inflammation that is observed in the liver. The utilization of 454 
murine SGVHD provides an opportunity to study the immune responses involved in both 455 
the initiation and progression of IBD-associated chronic liver inflammation. 456 
 457 
It has been suggested that the lymphocytic infiltration that is seen in IBD-458 
associated liver inflammation is comprised of cells that were activated within the gut and 459 
have migrated to the liver, aided by the aberrant expression of gut homing molecules 460 
(1).  Studies in the SGVHD model have shown that colon CAM expression is elevated 461 
during CsA-therapy as early as day 14 post-BMT and CD4+ T cells begin to accumulate 462 
in the colon at this time as well. (Perez et al. Accumulation of CD4+ T cells in the colon 463 
of CsA-treated mice following myeloablative conditioning and bone marrow 464 
transplantation.  Submitted for publication)(10).  While the basis for this early induction 465 
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of CAMs  and T cell accumulation in the colon is not known at this time, we hypothesize 466 
that pretransplant radiation and CsA treatment in the early post BMT period result in the 467 
production of inflammatory mediators including TNF-α.  At least two possibilities exist to 468 
explain the early proinflammatory response that occurs during the induction of SGVHD.  469 
First, both radiation and CsA have been shown to induce oxidative stress and 470 
transcription factors (14, 51, 60, 64) that could mediate the upregulation of inflammatory 471 
cytokines (12, 25, 34, 63).  In addition to direct involvement in the production of 472 
inflammatory mediators, irradiation and CsA have been shown to damage the gut 473 
leading to increased leakage of bacteria (18).  The interaction of TLR on innate effector 474 
cells with microbial products (PAMPs) is an alternative pathway that could focus the 475 
enhanced production of proinflammatory cytokines such as TNF-α within the colon, 476 
leading to increased expression of CAM and in accumulation of CD4+ T cells in the 477 
colons of CsA-BMT animals.  Why the expression of these molecules is delayed in the 478 
liver, is not clear at this time, but may relate to differences in the effects of the inductive 479 
therapy on the target organs.  Based on real time PCR data, MAdCAM-1 mRNA was 480 
not elevated at day 14 post-BMT, but along with the chemokine, CCL25, trended 481 
towards increased levels in the livers of CsA-treated mice by day 21 post-BMT (Fig.7).  482 
Few, if any, CD4+ T cells were observed in the livers in the early post-transplant period 483 
(days 14 or 21)(Fig. 7), but were observed during active disease (Figs.4, 7).  484 
Phenotypically, increased numbers of CD4+ T cells expressing markers of intestinal-485 
derived T cells, β7 integrin and CCR9, were found in the livers of SGVHD animals when 486 
compared to controls.   Together, these findings suggest CD4+ effector cells are 487 
activated in the intestinal tract and that an ordered migration of CD4+ T cells from the 488 
colon into the liver of SGVHD animals exists. 489 
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 490 
Hepatic T lymphocytes found in IBD-associated liver inflammation express the 491 
CCR9+ α4β7+ phenotype classically seen in lymphocytes that have been activated by gut 492 
DC’s (2).  Abnormal expression of the mucosal addressin, MAdCAM-1, along with the 493 
gut-associated chemokine CCL25 has been observed at elevated levels in the liver 494 
endothelium in PSC (1, 26) and provided a mechanism by which CCR9+ T cells 495 
activated in the intestinal tract can migrate to the liver.  The mechanisms by which these 496 
inflammatory molecules are upregulated in the liver are unknown but may involve the 497 
activation of TLR ligands with microbial PAMPS that arrive in the liver via entero-hepatic 498 
circulation resulting in the production of inflammatory mediators.  Levels of TLR mRNA 499 
that bind bacterial PAMPS, as well as TLR-expressing myeloid LAM were elevated in 500 
livers from SGVHD animals (Supplementary Fig. 1, 2).  This is supported further by 501 
previous data demonstrating that increased numbers of bacteria can be detected in the 502 
livers of CsA treated mice during the induction of SGVHD (18).  Furthermore, similar to 503 
peripheral effector cells from diseased animals (6), the LAM’s isolated from SGVHD 504 
mice demonstrated an increased proliferative response to bacterial antigen-pulsed APC.  505 
We have previously shown that isolated CD4+ T cells from the peripheral lymphoid 506 
tissues of SGVHD mice could adoptively transfer colitis and liver inflammation into 507 
secondary recipient animals (6).  The ability of LAM isolated from the livers of SGVHD 508 
mice to transfer disease to secondary recipient animals has yet to be determined.  509 
  510 
Damage to liver bile ducts during IBD-associated liver inflammation is thought to 511 
be mediated by TH1, CD4+, IFN-γ-producing T cells. Hepatocellular damage through 512 
IFN-γ is thought to occur by a variety of mechanisms including direct cellular injury, 513 
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modulation of Ag presentation, and both the recruitment and activation of other immune 514 
cells (15, 55).  However, the immune phenotype of the cells that induce autoimmune 515 
chronic liver inflammation has come into question, with TH17 immunity being observed 516 
as well (22, 45).  Data presented here indicates that TH17 cells, determined by 517 
increased intracellular cytokine production of IL-17 by CD4+ LAM and increased mRNA 518 
levels of TH17 associated cytokines (IL-17, IL-23p19, TNF-α), were increased in the 519 
livers of SGVHD mice. We have also found a significant increase in TH17 associated 520 
cytokines in the colons of SGVHD mice (Brandon et al. Development of a TH17 immune 521 
response during the induction of murine syngeneic graft-versus-host disease, Submitted 522 
for publication). This increase was observed even at day 21 post BMT in CsA-treated 523 
mice suggesting that TH17 T cells may have an important role in SGVHD-associated 524 
colitis.  As increased percentages of CD4+TH1 were also found in diseased livers, the 525 
role that TH17 and TH1 CD4+ T cells play during SGVHD-induced chronic liver 526 
inflammation remains to be determined.  It should be noted that while TH17 cells are 527 
present in the PBC livers of IL-2Rα-/- animals, a model of chronic liver inflammation, the 528 
data suggests that the IL-17 secreting cells differentiate in the liver and appear not to be 529 
recruited from other sites (33), with no enterohepatic linkage being observed in the 530 
development of the autoimmune PBC.  Finally, both TH17 and TH1 cells have both been 531 
detected in an autoimmune model of skin inflammation.  These cells developed with 532 
different kinetics with TH17 cells emerging early, being replaced by a TH1 CD4+ immune 533 
response later in the disease process (37).   534 
It is likely that altered immune regulation in the periphery and in the liver following 535 
induction of SGVHD contributes to the development of the chronic inflammatory 536 
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responses described in the current manuscript.  CD4+ regulatory T cells have been 537 
shown to regulate the development of spontaneous and inducible murine colitis (3).   538 
Hess et al. have demonstrated that altered regulatory T cell activity contributed to the 539 
development of rat SGVHD with reduced numbers of regulatory lymphocytes being 540 
observed in diseased animals (24).  Similarly, in a model of CsA-induced autoimmunity, 541 
it was shown that reconstitution of CD4+CD25+ regulatory T cells was delayed until after 542 
cessation of CsA treatment (62).  With these findings in mind we have demonstrated 543 
that at the time of cessation of CsA therapy, significantly reduced numbers of 544 
CD4+CD25+FoxP3+ T cells are present in the spleen and MLN of CsA-treated animals 545 
(J.S. Bryson, unpublished observations).   Similar to the reduced expression of 546 
regulatory T cells in the SGVHD animal, results presented in the current manuscript 547 
demonstrated that another T cell population with regulatory potential, iNKT cells, was 548 
significantly reduced in the livers of SGVHD versus control BMT animals (Fig. 4E).  549 
Invariant NKT cells in the mouse express a single invariant Vα TCR chain (Vα14Jα18) 550 
(reviewed (31)), are positively selected to the nonclassical MHC molecule CD1d, have 551 
strong reactivity to the glycosphingolipid α-galactosylceramide (α-GalCer) and are 552 
present in high numbers in the liver.  Liver iNKT cells have been shown to participate in 553 
the induction of oral tolerance (29, 57), tolerance to antigens in privileged sites (47) and 554 
inhibit the development of experimental colitis in mice (41, 46, 56). Significant 555 
reductions in CD4+ Treg and iNKT are observed in the periphery and livers of SGVHD 556 
animals respectively.  Thus, as a result of CsA therapy, reconstitution of these important 557 
regulatory immune populations is delayed and uncontrolled expansion of T effector cells 558 
occurs resulting in the development of chronic colon and ultimately, liver inflammation.  559 
In line with this hypothesis, we have demonstrated that recovery from SGVHD (approx. 560 
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30% of diseased animals) is associated with increases in regulatory T cells and iNKT 561 
cells and that CD4+CD25+ regulatory T cells from normal mice inhibited the adoptive 562 
transfer of SGVHD ((6) J. S. Bryson, unpublished observations) demonstrating the 563 
potential role of these cells in controlling chronic inflammation in this model system. 564 
In other murine models of colitis the development of chronic liver inflammation 565 
was only observed in approximately 30% of mice (40).  Significant and reproducible 566 
inflammatory liver lesions of bile ducts was observed in 100% of SGVHD mice in 567 
association with increased inflammatory mediators within the liver that are normally 568 
associated with colitis.  Furthermore, significant changes in inflammatory markers 569 
associated with chronic liver inflammation were observed, suggesting a mechanistic 570 
relationship between the development of SGVHD- induced liver inflammation and that 571 
observed in the early stages of clinical disease.  Similarities include the induction of 572 
inflammatory molecules that result in the influx of CCR9+ β7integrin+ CD4+ T cells and 573 
inflammation of the intra and extrahepatic bile ducts.  And while the model mimics many 574 
aspects of the disease process associated with clinical chronic liver inflammation, at the 575 
time points analyzed thus far, little to no sclerosis has been observed.  Whether this is a 576 
limitation of the model or merely a timing issue in relation to disease induction remains 577 
to be elucidated.   With the enterohepatic linkage and the previously published role of 578 
CD4+ T cells in the SGVHD model (6, 10), the inflammatory response seen in these 579 
animals may provide an opportunity to study the pathobiology involved in both the 580 
initiation and progression of IBD-associated, chronic liver inflammation. 581 
582 
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FIGURE LEGENDS 588 
Figure 1. 589 
Histological examination of SGVHD livers showed development of chronic liver 590 
inflammation during murine SGVHD.  To induce SGVHD C3H/HeN mice were lethally 591 
irradiated, reconstituted with syngeneic BM and treated daily for 21 days with CsA 592 
(15mg/kg/day) or the diluent olive oil.  Tissues were taken when animals exhibited 593 
clinical symptoms (weight loss, diarrhea) of SGVHD-induced colitis (2-4 or 8 weeks 594 
post-CsA).  (A) Control colon (H&E) demonstrating normal histology.  (B) Colon from 595 
SGVHD animal (H&E) showing transmural inflammation with apoptotic cells, glandular 596 
invasion, crypt abscess formation and complete glandular destruction.  Liver tissue from 597 
SGVHD animals (8 weeks post CsA) showing portal inflammation (D)(H&E) with focal 598 
extension beyond the limiting plate (E)(H&E),(F)(Trichrome) arrows. Transplant control 599 
liver (C)(H&E). Extra-hepatic bile ducts were isolated from control and SGVHD animals 600 
3 weeks post CsA therapy.  Control (G)(H&E) samples demonstrated mild surrounding 601 
inflammation of the common and branching bile duct.  Samples of extra-hepatic bile 602 
ducts from SGVHD mice (H)(H&E) showed apoptotic changes in bile duct epithelium 603 
(small arrow) and invasion of bile duct epithelium by inflammatory cells in the common 604 
duct and branches. Inflammatory debris was present in the lumen and inflammatory 605 
cells in the surrounding adventitia.  All tissues were photographed at 200X 606 
magnification. 607 
 608 
 609 
 610 
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Figure 2. 611 
Increased colon and liver pathology associated with induction of SGVHD.  Pathology 612 
grading of tissues was performed (9).  Data represents mean grade ± SEM of samples 613 
from 2 experiments (n=9) and significance was determined using the unpaired Student’s 614 
t test. 615 
 616 
Figure 3. 617 
Markers of chronic liver inflammation associated with SGVHD. Serum/plasma was 618 
isolated from BMT control or SGVHD mice 3-6 weeks after cessation of CsA therapy 619 
during active disease.  Levels of ALT (A), anti-ssDNA (B) and p-ANCA (C) were 620 
determined as described in Methods.  Left panels represent pooled data, mean ± SEM 621 
from 3 experiments collected at 2-6 weeks post CsA therapy.  The data presented in 622 
right panels represents time course at time points after cessation of induction therapy 623 
(n=number of samples analyzed).  Significance was determined using unpaired 624 
Student’s t test, or Fisher’s exact test, p-ANCA right panel. 625 
 626 
Figure 4.  627 
Increased CD4+ T cell localization around the hepatic bile ducts in SGVHD livers. Liver 628 
associated mononuclear cells (LAM) were isolated from BMT control and SGVHD mice 629 
2-4 weeks after cessation of CsA therapy. The percentage of CD4+ and CD8+ T cells 630 
(data from 5 pooled experiments) (A), percentage of CD4+ LAM that are β7 integrin+ or 631 
CCR9+ (B) (n=4 animals), iNKT (α-GalCer CD1+ tetramer) (data from 3 pooled 632 
experiments normal n=2, control n= 3 and CsA n=6) (E) and CD11b+ (F) (data from 4 633 
pooled experiments) were determined by FACS analysis. Liver sections from transplant 634 
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control (C) and SGVHD mice (D) were examined by immunohistochemistry for presence 635 
of CD4+ T cells.  Significance was determined using unpaired Student’s t test. 636 
 637 
 638 
Figure 5 639 
Increased levels of TH1 and TH17 immunity in the livers of SGVHD mice.  At the time of 640 
active disease mice were euthanized, livers removed and pooled from 3-4 641 
animals/experimental group.  (A) LAM were isolated from the pooled liver preparations 642 
as described in the Methods Section, stimulated with anti-CD3 for 8 h with monensin 643 
being added during the last 4 h of culture.  The cells were processed for intracellular 644 
cytokine staining of IL-17 and IFN-γ.  Graphs represent mean ± SEM and is pooled data 645 
from 4 experiments.  Significance determined using paired Student’s t test. (B) Hepatic 646 
mRNA was extracted and cDNA prepared.  Samples were analyzed for cytokine mRNA 647 
using real time RT-PCR for IL-23p19, IL-12p40 and TNF-α. Expression of these genes 648 
was normalized to GAPDH using the ΔΔCT method. Represents pooled data from 3 649 
experiments, n=12 (IL-23p23, IL-12p40), n=8 (TNF-α) and significance was determined 650 
by unpaired Student’s t test.   651 
 652 
Figure 6. 653 
Increased levels of liver inflammatory chemokines and adhesion molecules in SGVHD 654 
livers. Hepatic mRNA was extracted from SGVHD mice and cDNA prepared.  655 
Inflammatory chemokine and adhesion molecule mRNA was analyzed using real time 656 
RT-PCR for the primers CCL25, CCL28 CCR9 and MAdCAM-1. Expression of these 657 
genes was normalized to GAPDH using the ΔΔCT method. Represents pooled data 658 
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from 3 experiments, n=12 per group with significance determined using unpaired 659 
Student’s t test.   660 
 661 
Figure 7. 662 
CD4+ T cells migrate to the liver after cessation of CsA therapy. Livers were isolated at 663 
14, 21 and 37 days from SGVHD and control animals and analyzed (A) by 664 
immunohistochemistry for the presence of CD4+ T cells or (B) for MAdCAM mRNA 21 665 
days after BMT by real time RT-PCR.  Data presented representative of (A) 4 tissues 666 
from two experiments,  (B) or pooled samples (mean ± SEM) from two experiments, n=8 667 
and were analyzed using unpaired Student’s t test. 668 
 669 
Figure 8. 670 
LAM from SGVHD livers showed an increase proliferative response to CeAg-pulsed DC. 671 
Liver associated mononuclear cells (LAM) were isolated from BMT control and SGVHD 672 
mice four weeks after cessation of CsA therapy.  Proliferation against CeAg-pulsed DC 673 
in the presence or absence of anti-CD4 mAb was measured by thymidine incorporation 674 
during the last 18 to 96 h assay. Data comparing CeAg-induced proliferation 675 
representative of 3 experiments and represents mean ± SEM of triplicate samples and 676 
significance was determined using unpaired Student’s t test.  CD4 blocking represents 677 
results from a single experiment. *Different from control LAM stimulated with DC-CeAg 678 
p=0.0209. **Different from SGVHD DC-Ag p=0.0231 679 
 680 
 681 
32 
 
SUPPLEMENTAL FIGURE LEGENDS 682 
 683 
Supplemental Figure 1. 684 
SGVHD mice showed increased liver TLR mRNA. SGVHD was induced as described.  685 
At 2-4 weeks post-CsA mice were euthanized and their livers removed.  Hepatic mRNA 686 
was extracted and cDNA prepared.  Samples were analyzed using real time RT-PCR 687 
for the primers TLR 2,4,5 & 9 (A-D respectively) and the expression of these genes was 688 
normalized to GAPDH using the ΔΔCT method. Represents pooled data from 3 689 
experiments, n=12 per group and significance was determined using unpaired Student’s 690 
t test.  691 
 692 
Supplemental Figure 2. 693 
Increased TLR expression in LAM isolated from SGVHD.  LAM were isolated from 2-4 694 
weeks post-CsA therapy from 2-4 control and SGVHD animals and pooled within each 695 
treatment group.  The cells were stained for the surface and intracellular expression of 696 
CD11b and TLR2 and TLR5.  RAW264.7 cells were utilized as positive control for TLR 697 
staining and were positive for TLR2. A. Representative flow diagrams for staining of 698 
TLR2 and TLR5.  B. Pooled results from three experiments analyzing expression of 699 
TLR2 and TLR5 in LAM from control and SGVHD mice.  Significance determined using 700 
unpaired Student’s t test. 701 
 702 
 703 
 704 
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